Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glycotex obtains active IND for wound healing drug
The Phase IIa human clinical trial to be conducted in the US is designed to investigate the safety and clinical outcomes of topically applied GLYC-101 compared to placebo
The Phase IIa human clinical trial to be conducted in the US is designed to investigate the safety and clinical outcomes of topically applied GLYC-101 compared to placebo
The initial phase of the multiple ascending dose (MAD) study utilized three times per day dosing (tid) for 14 days in healthy obese subjects exposed to a high
Under the terms of the collaboration agreement, Seattle Genetics received an upfront payment of $60 million in February 2007, and is entitled to receive potential milestone payments exceeding
Greatbatch’s acquisition of Precimed was structured as a stock purchase. In exchange for the outstanding shares of Precimed, Greatbatch paid approximately CHF123 million in cash and, under terms
The uniquely designed Phase I dose-escalation study in adult patients with advanced cancer will investigate the safety and preliminary efficacy of CNDO101 (5-imino-13 deoxy-doxorubicin). The trial has eight
In the initial Phase I part of the study, safety and pharmacokinetics of combining XL184 with erlotinib will be evaluated. The primary endpoint of the Phase II part
The series B financing was led by Bay City Capital and included Integral Capital Partners as well as current investors Delphi Ventures and Onset Ventures. Peter Edelstein, president
Under the strategic agreement, the companies expect to launch two products in the first half of 2008. IntelGenx will complete the development of the products, using its patented
The Personal Diabetes Manager (PDM) with integrated DexCom technology is expected to broaden Insulet’s portfolio of diabetes management products. The development agreement between Insulet and DexCom also contemplates
The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding